Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation

Abstract

The present study was designed to determine the pharmacokinetic profiles of a once-daily formulation of tacrolimus (CAS 104987-11-3; TAC-once) in patients before and after introduction of renal transplantation. Pharmacokinetic parameters for tacrolimus were almost comparable among patients receiving TAC- once before, 2 weeks after and 3 weeks after renal transplantation. Among various parameters, C_trough correlated most closely with the area under the concentration-time curve during 24 h (AUC_0–24) (R² = 0.82, P < 0.001), while no consistent correlation was observed between AUC_0–24 and concentrations at 2 h or 4 h, or the dose of TAC-once. The clinical outcomes such as the incidence of acute rejection, renal tissue injury and cytomegalovirus infection were evaluated during the first 3 weeks and 3 months after transplantation, and the data were compared with the historical data obtained from patients who had received the conventional twice-daily formulation of tacrolimus (TAC-twice). There were no significant differences in the incidence of such clinical outcomes between the two groups. These findings suggest that C_trough is useful for therapeutic monitoring of tacrolimus in patients receiving TAC-once. In addition, pharmacokinetics and clinical outcomes were comparable between TAC-once and TAC-twice formulations.

Key words

Area under the concentration-time curve - CAS 104987-11-3 - Pharmacokinetics - Renal transplantation - Tacrolimus, once-daily formulation - Trough concentration

• References

• 1 Japanese FK 506 Study Group. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Transplant Proc. 1991; 23: 3085-8
• 2 Cross SA, Perry CM. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs. 2007; 67: 1931-43
• 3 Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009; 31: 139-52
• 4 Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009; 9: 2505-13
• 5 Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999; 31: 296-8
• 6 Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43: 623-53
• 7 First MR. First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit. 2008; 30: 159-66
• 8 Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J et al. Time-related clinical determinants of longterm tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004; 43: 741-62
• 9 Wente MN, Sauer P, Mehrabi A, Weitz J, Büchler MW, Schmidt J et al. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation. Clin Transplant. 2006; 20 (Suppl 17) 80-4
• 10 Mathew BS, Fleming DH, Jeyaseelan V, Chandy SJ, Annapandian VM, Subbanna PK et al. A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2008; 66: 467-72
• 11 Jørgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant. 2002; 17: 1487-90
• 12 Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007; 63: 1039-44
• 13 Silva Jr HT, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007; 7: 595-608
• 14 Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extendedrelease formulation in stable kidney transplant recipients. Transplantation. 2007; 83: 1648-51
• 15 Diez Ojea B, Alonso Alvarez M, Aguado Fernández S, Baños Gallardo M, García Melendreras S, Gómez Huertas E. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc. 2009; 41: 2323-5
• 16 Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008; 66: 207-14
• 17 Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-75
• 18 Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant. 2009; 24: 2269-76